Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
Associate PartnerAssociate Partner
LIVE TV DownloadNews18 App
News18 English
News18 » India
1-min read

Govt Invokes Emergency Clause to Maintain Production of Coronary Stents

The government on Tuesday made it mandatory for stent makers to maintain production and supply of coronary stents by invoking an emergency clause under drug price control law citing reports of shortage in market.

Press Trust Of India

Updated:February 21, 2017, 7:46 PM IST
facebookTwitterskypewhatsapp
stent
In this file photo, a heart surgeon holds a stent, which is inserted into constricted coronary arteries to help keep them open and normalise blood flow. (Reuters)

New Delhi: The government on Tuesday made it mandatory for stent makers to maintain production and supply of coronary stents by invoking an emergency clause under drug price control law citing reports of shortage in market.

"After due deliberations on the current situation and alternatives available with the government to resume normal supply of the coronary stents, it has been decided to invoke the powers of Section 3 (i) of DPCO, 2013," Department of Pharmaceuticals said in a letter to stent makers.

The department said there have been reports of shortage of coronary stents in the market/hospitals.

Last week, the government had slashed prices of stents by up to 85 percent by capping them at Rs 7,260 for bare metal ones and Rs 29,600 for the drug eluting variety.

Under the Section 3 (i) of DPCO, 2013, the government can regulate distribution and direct any manufacturer to increase production and sell products to institutions, hospitals or any agency as the case may be in case of emergency or in circumstances of urgency or in case of non-commercial use in public interest.

In its letter to the manufacturers, the department said: "The companies manufacturing stents in India are directed to maintain production/import/supply of the stents and to submit a weekly report on stents produced and distributed. They will also submit a weekly production plan for the next week to NPPA and DCGI".

The National Pharmaceutical Pricing Authority (NPPA) andthe Drug Controller General of India (DCGI) are also empowered to extend these directions to "any other producers of coronary stents in India during this three months period," it added.

The order will be valid for next six months and NPPA and DCGI will recommend withdrawal or extension as the case may be, two weeks before the expiry of the period, it added.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, Telegram, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

| Edited by: Bijaya Das
Read full article
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp

Live TV

Countdown To Elections Results
To Assembly Elections 2018 Results